Deep-tech: 19 successful projects

Lumedix - SATT Paris-Saclay

LUMEDIX

Next-generation in vitro diagnostics

LumediX has developed a technology to increase the sensitivity of in vitro diagnostic tests by a factor of 100 to 1000.

CEO: Maximilian Richly

Creation: july 2018

Headcount: 5

Location: Palaiseau

Market(s): In vitro diagnostics

www.lumedix.com

#InVitroDiagnostics #Nanoparticles #PointOfCare

TECHNO / PRODUCTS

Lumedix technology is based on luminescent rare-earth-based nanoparticles, which can suit to any type of immunoassay and lower the
minimum detectable concentration of any type of immunoassay by several orders of magnitude.

PRODUCTS PORTFOLIO

  • Feasibility studies
  • Licensing of luminescent nanoparticles
  • Diagnostic tests proprietary

APPLICATIONS

LumediX initially applies its technology in the field of rapid diagnostics tests (“Point-of-Care”, “Point-of-Use”), giving them analytical sensitivities equivalent to tests performed today in analytical laboratories.

BENEFITS

Lumedix nanoparticles, acting as detection probes, produce a higher signal-to-noise ratio than conventional probes, thanks to their unique physicochemical properties, hence producing a test with superior analytical sensitivity than current marketed probes.

LUMEDIX MINUTE